| PRECLINICAL | evidence | A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Challenges in the management of obesity. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025). | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Re "Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA" - Perspective on potential weight-independent effects. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Physiology, Gastric Inhibitory Peptide. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | The lack of efficacy of tirzepatide in mitigating cisplatin-induced neurotoxicity and cognitive impairment in rats. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare? | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Current clinical application of incretin therapy for obesity management. | Zepbound | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Achieving BMI <25 kg/m(2) was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Pharmacological progress in obesity: tirzepatide's rising advantage over semaglutide. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet. | Tirzepatide | Glycemic control | 2025-12-29 |
| PRECLINICAL | evidence | 12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis. | Tirzepatide | — | 2025-12-26 |
| PRECLINICAL | evidence | The evolving role of metabolic and bariatric surgery in contemporary clinical practice. | Tirzepatide | — | 2025-12-26 |
| PRECLINICAL | evidence | Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model. | Tirzepatide | — | 2025-12-23 |
| PRECLINICAL | evidence | Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea. | Tirzepatide | — | 2025-12-20 |
| PRECLINICAL | evidence | The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review. | Tirzepatide | Lipid & cardiovascular markers | 2025-12-19 |
| PRECLINICAL | evidence | Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review. | Tirzepatide | Weight & fat loss | 2025-12-18 |
| PRECLINICAL | evidence | Medications for Obstructive Sleep Apnea. | Tirzepatide | — | 2025-12-17 |
| PRECLINICAL | evidence | Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome. | Tirzepatide | — | 2025-12-17 |
| PRECLINICAL | evidence | Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. | Tirzepatide | Glycemic control | 2025-12-17 |
| PRECLINICAL | evidence | Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide. | Tirzepatide | — | 2025-12-17 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction. | Tirzepatide | — | 2025-12-16 |
| PRECLINICAL | evidence | Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease. | Tirzepatide | — | 2025-12-16 |
| PRECLINICAL | evidence | Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide. | Tirzepatide | — | 2025-12-14 |
| PRECLINICAL | evidence | The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials. | Tirzepatide | — | 2025-12-13 |
| PRECLINICAL | evidence | Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis. | Tirzepatide | Glycemic control | 2025-12-10 |
| PRECLINICAL | evidence | Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders. | Mounjaro | — | 2025-12-09 |
| PRECLINICAL | evidence | Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis. | Tirzepatide | — | 2025-12-08 |
| PRECLINICAL | evidence | Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report. | Tirzepatide | — | 2025-12-06 |
| PRECLINICAL | evidence | Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro. | Tirzepatide | Inflammation · preclinical | 2025-12-06 |
| PRECLINICAL | evidence | The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis. | Tirzepatide | Addiction & substance use | 2025-12-05 |
| PRECLINICAL | evidence | Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation. | Tirzepatide | Glycemic control | 2025-12-05 |
| PRECLINICAL | evidence | Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy. | Tirzepatide | — | 2025-12-02 |
| PRECLINICAL | evidence | [A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide]. | Tirzepatide | — | 2025-12-02 |